Skip to main content

JAK/TYK2

      RT @RichardPAConway: Dougados et al. MACE in tofa clinical programme. Baseline CV risk important. Overall MACE IR 0.38
      2 years 5 months ago
      Dougados et al. MACE in tofa clinical programme. Baseline CV risk important. Overall MACE IR 0.38 [0.26-0.54]. MACE IR lower than in ORAL Surveillance in CV enriched pop 0.72 [0.46-1.09]. @RheumNow #EULAR2022 OP0264 https://t.co/lGTTEx0X5p https://t.co/MvD6kjkpse
      RT @AurelieRheumo: 🧫 JAKi and NK
      cells activation:
      JAKi and particularly TOFA impacts NK cells:
      *phenotype
      *functio
      2 years 5 months ago
      🧫 JAKi and NK cells activation: JAKi and particularly TOFA impacts NK cells: *phenotype *function *impairs the control of proliferation of lung cancer and lymphoma cell lines An explanation for the increase of cancer events in ORAL surveillance? @RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU
      RT @Janetbirdope: MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs
      2 years 5 months ago
      MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs #TNFis @RheumNow @eular_org #EULAR2022 OP0135 https://t.co/O8iOA7jpal
      RT @drdavidliew: Was ORAL Surveillance really a surprise?
      Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b
      2 years 5 months ago
      Was ORAL Surveillance really a surprise? Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b/4 +LTE) Cardiovascular risk-enriched pts were always in the same MACE ballpark with tofa ORAL Surveillance was worse, but clues were always there OP0264 #EULAR2022 @RheumNow https://t.co/rB5SwVX2oc
      RT @RichardPAConway: Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE
      2 years 5 months ago
      Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE in MACE ROR=0.87 [95%CI 0.80-0.95]. INCREASE in DVT: ROR=3.99 [3.15-5.04], PE: ROR=3.47 [2.90-4.13] @RheumNow #EULAR2022 OP0268 https://t.co/lUin7ciXWt https://t.co/Gr4Kvd8F7R
      RT @drdavidliew: MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it?

      Vigibase: MACE (really MI)
      2 years 5 months ago
      MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it? Vigibase: MACE (really MI) & VTE signals there before the scare Always chance regulatory warnings cause stimulated reporting but signal here was clear before RCT-driven alerts OP0268 #EULAR2022 @RheumNow https://t.co/hTJD1gMgyy
      Video: Further Considerations of the ORAL Surveillance Study

      Further Considerations of ORAL Surveillance Study - this w
      2 years 5 months ago
      Video: Further Considerations of the ORAL Surveillance Study Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022 https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT
      Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) presented on the first day of…
      Translating targeted therapy from bench to bedside has been more problematic in systemic lupus erythematosus (SLE) than other autoimmune diseases, with many theoretically well-founded agents…